₹-125.00
(Market cap
₹54,085 Cr
Recently Viewed
Clear AllMarket cap
₹54,085 Cr
Revenue (TTM)
₹6,824 Cr
P/E Ratio
35.5
P/B Ratio
12.3
Div. Yield
1.9 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹1,524 Cr
ROE
36 %
ROCE
47.9 %
Industry P/E
29.53
EV/EBITDA
24.8
Debt to Equity
0
Book Value
₹2064.5
EPS
₹717.3
Face value
10
Shares outstanding
21,249,302
CFO
₹6,626.30 Cr
EBITDA
₹8,993.31 Cr
Net Profit
₹7,030.84 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abbott India
| -12.8 | -3.2 | -8.6 | -14.8 | 4.5 | 10.7 | 18.4 |
|
BSE Healthcare
| 2.7 | 5.1 | 8.1 | 6.5 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Abbott India
| -3.3 | 30.7 | 6.9 | 9.7 | 23.7 | 20.0 | 72.5 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abbott India
|
25,300.0 | 54,085.0 | 6,824.1 | 1,524.1 | 25.9 | 37 | 35.5 | 12.3 |
| 5,408.0 | 63,949.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,424.7 | 82,337.3 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 23.6 | 2.3 | |
| 362.7 | 58,644.4 | 16,827.4 | 629.6 | 9.6 | -0.1 | 97.1 | 1.5 | |
| 2,420.0 | 41,421.5 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.6 | 20.7 | |
| 1,533.2 | 39,005.8 | 9,504.5 | 947.8 | 15.9 | 14.6 | 42.9 | 5.0 | |
| 2,297.5 | 1,06,259.9 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.9 | 5.1 | |
| 2,263.6 | 93,546.9 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 52.6 | 6.0 | |
| 1,745.6 | 4,15,996.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 38.1 | 5.1 | |
| 911.9 | 93,765.9 | 26,089.3 | 4,933.9 | 24.7 | 21 | 19 | 3.6 |
10 rock-solid stocks with stable earnings
17 min read•By Udhayaprakash, Mithilesh Bhaumik, Shubham Dilawari and Kunal Bansal
Stock Rating update, March 22, 2024
2 min read•By Value Research
2 min read•By Value Research
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty,... including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited. Read more
Incorporated
1944
Chairman
Munir Shaikh
Managing Director
Kartik Rajendran
Group
Abbott India - MNC
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Abbott India Ltd is ₹25,300.00 (NSE) and ₹25,290.00 (BSE) as of 28-Apr-2026 13:54 IST. Abbott India Ltd has given a return of 4.54% in the last 3 years.
The P/E ratio of Abbott India Ltd is 35.49 times as on 27-Apr-2026, a 20 premium to its peers’ median range of 29.53 times.
The P/B ratio of Abbott India Ltd is 12.33 times as on 27-Apr-2026, a 170 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.17
|
15.53
|
|
2024
|
47.67
|
15.65
|
|
2023
|
49.43
|
14.92
|
|
2022
|
47.09
|
13.55
|
|
2021
|
46.11
|
12.45
|
The 52-week high and low of Abbott India Ltd are Rs 37,000.00 and Rs 25,150.00 as of 28-Apr-2026.
Abbott India Ltd has a market capitalisation of ₹ 54,085 Cr as on 27-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Abbott India Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.